Cassava Sciences (SAVA)

• Market cap: $142M
• 1 day: -9.82%
• 5 days: 2.44%
• 1 month: -28.29%
• 3 months: 28.95%
• 6 months: 58.06%
• Year to date: 6.91%
• 1 year: -88.32%
• 5 years: -64.87%
• 10 years: -77.89%
• Sector: Healthcare
• Industry: Biotechnology

About: Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.

Employees: 30